Antibiotics Test Questions – Flashcards

Unlock all answers in this set

Unlock answers
question
where do antibiotics come from?
answer
they are naturally produced by bacteria and fungi, some are modified or entirely synthetic
question
what does it mean that antibiotics are selectively toxic?
answer
that they kill/injure invading organisms w/o harming cells of the host. however, to varying degrees, some antibiotics are toxic or have side effects
question
what does it mean to say that an antibiotic is bacteriostatic?
answer
it reversible inhibits metabolic processes of bacteria, (stops growth)
question
what does it mean to say that an antibiotic is bactericidal? can bacteriostatic antibiotics be bactericidal at higher doses?
answer
this kind of antibiotic kills susceptible bacteria. some bacteriostatic antibiotics can be bactericidal at higher doses.
question
what does it mean to say that a drug has a narrow spectrum of activity? extended? broad?
answer
narrow spectrum antibiotics will only act on a single or limited group of microbes. extended spectrum antibiotics can be modified to be effective against gram + and gram – organisms. broad spectrum antibiotics are active against a wide range of bacteria
question
what is the difference between antibiotic susceptible and resistant bacteria?
answer
susceptible: in vitro and in vivo susceptibility means the growth can be inhibited or killed by antibiotic.
resistant: in presence of antibiotic the organism will continue to grow and live
question
can some antibiotics be static for some organisms and cidal for others? what would be a reason for using specifically bacteriocidal drugs?
answer
some organisms that remain alive at all in the presence of a drug can still make toxin, so bacteriocidals might be needed. also some bacteriocidal drugs like PCN can kill but not at once, while erythromycin stops toxin productin immediately.
question
what do the best antibiotics target?
answer
the best antibiotics target biosynthetic processes that are only in bacteria, and not in eukaryotic cells.
question
what is the first line of antibiotics to be considered?
answer
antibiotics that inhibit cell wall synthesis, b/c peptidoglycan can't be found in eukaryotic cells.
question
what are PCN binding proteins, PBPs?
answer
PBPs bind transpeptidases that are involved in peptidoglycan cross-linking
question
what are beta lactams? what is their degree of toxicity?
answer
antibiotics with a beta lactam ring which bind to PBPs which are transpepsidases. PCN, cephalosporin are examples. they have low toxicity.
question
how do beta lactams work?
answer
beta lactams bind transpeptidases (PBPs) preventing peptidoglycan cross-linking while the organism is growing and cross-linking can no longer occur, causing lysis of the organism. the organism has to be growing however for the drug to work.
question
what is a method of resistance, (MOR) that bacteria can use against beta lactams?
answer
beta lactamases cleave the beta lactam ring, which inactivates antibiotic
question
what is a MOR gram - bacteria can use to keep antibiotics out?
answer
spontaneous mutations of porins where antibiotics cannot enter organism
question
what is a MOR MRSA uses to fight PCN?
answer
alteration of PBPs that keeps PCN from binding
question
how does vancomycin work? what is a MOR against it?
answer
vancomycin interacts with D-ala, D-ala termini preventing cross-linkage of peptidoglycan layers. some organisms change to D-ala, D-lac - which vancomycin doesn't bind to
question
how does bacitracin work?
answer
bacitracin prevents movement of peptidogylcan precursors through the cytoplasmic membrane to the cell wall
question
how does polymyxin work?
answer
polymyxin inserts itself into gram - outer membranes by interacting with LPS and phospholipids, and interrups the membrane
question
what are the cell wall antibiotics?
answer
beta lactams, (PCN, cephalosporin, bind PBPs while organism is growing. vancomycin binds D-ala, D-ala, preventing cross-linkage of peptidoglycan layers. bacitracin, which prevents movement of peptidoglycan precursors through the cytosol. polymyxin which inserts itself into the outer membrane of gram - bacteria.
question
what do antibiotics that inhibit protein synthesis target? are there selective toxicity concerns for these?
answer
these disrupt the ribosomes. prokaryotes have 70s, (total), ribosomes while eukaryotes have 80s,(total), these are techinically different, but some similarities, so there is some effect on eukaryotic cell function, (tetracycline can affect teeth development and cause toxicity to renal tubules and inner ear)
question
what do aminoglycosides do? do they have to do anything first in orde to accomplish this?
answer
aminoglycosides bind to the 30s ribosome and cause premature release of the peptide chains. however to do this they must penetrate the gram - cell wall and associated with the active transport system, (oxidative)
question
what are MORs developed against aminoglycosides?
answer
obligate anaerobes have inactive transport. altered uptake of the drug. modification by addition of adenyl, acetyl or phosphoryl group, (plasmid, transposon encoded), mutation in ribosome -> no binding
question
how do tetracyclines work?
answer
these bind to the aminoacyl-tRNA site on the 30s ribosomal subunit and block its attachment to the acceptor site on mRNA ribosome complex, preventing protein synthesis.
question
what are some MORs against tetracycline?
answer
decreased uptake or active efflux of the drug from the bacteria mediated by a transporter it can aquire a gene for. (keeps antibiotic conc low inside cell)
question
what do macrolides do? what is an example of one?
answer
macrolides prevent polypeptide elongation at the 50S ribosome.
question
what are some MOR developed against macrolides?
answer
decreased cell uptake, enzymatic inactivation, and mutation causing decreased binding to ribosome
question
what are antibiotics that work to inhibit protein synthesis?
answer
aminoglycosides, (bind 30s, produce premature release of mRNA), tetracycline, (bind 30s, blocks aminoacyl-tRNA attachment to acceptor site on mRNA ribosome complex) macrolides, (prevent polypeptide elongation by binding to 50s subunit)
question
what are DNA gyrases? do eukaryotes have these?
answer
a topoisomerase that keeps cells from twisting around itself. eukaryotes do not have these.
question
what do quinolones do?
answer
block activity of DNA gyrase, prevent DNA from being replicated b/c it keeps getting twisted.
question
what is an MOR for quinolone?
answer
mutations in DNA gyrase so that it can no longer bind
question
what is rifampin?
answer
this inhibits DNA dependent RNA polymerase which inhibits initiation of transcription, by binding to the beta subunit
question
is RNA polymerase in prokaryotes different than that in eukaryotes?
answer
yes
question
what is a rifampin MOR?
answer
mutation in RNA polymerase that frequently happens when the anitbiotic is used alone
question
what are antibiotics that inhibit nucleic acid synthesis?
answer
quinolones, rifampin
question
what do sulfonamides do?
answer
inhibit dihydropteroate synthase which inhibits folic acid synthesis in prokaryotes.
question
what does trimethoprin do?
answer
inhibits dihydrofolate reductase, (bacteria need to make their own folic acid, they cannot use the folic acid humans make)
question
what antibiotics inhibit the metabolism?
answer
sulfonamides and trimethoprin
question
what some considerations in terms of selecing antimicrobial therapy?
answer
ID organism and susceptibility patterns, site of infection, pt factors, (age, liver/kidney disfunction, pregnant, immune status), pharmacologic factors, (delivery, distrobution, elimination, toxicity, interactions with other drugs)
question
what are the two ways of approaching antibiotic prescription?
answer
empirical theory or selection of therapy with known etiology
question
what is empirical theory?
answer
presumtive prescription of antibiotics, assuming you know the organism, susceptibility pattern, etc. justification is improvement of morbidity, mortality, or public health. (writing a rx for a pt you think has chlamydia/gonhorra, or for a pt you think has spinal menigitis)
question
what are considerations for empirical theory?
answer
knowledge of association between pathogen and disease: (streptococcus pneumonia = number 1 cause of pneumonia and meningitis, so you know what rx to write. pt hx: including age, immune status, disease state, pregnancy?, travel? broader spectrum of therapy: may be required to cover possible organisms that may be causing the infection
question
what is selection of therapy with known etiology? what should be considered in terms of what organism it is, what it will respond to, continuing conditions, and local environment?
answer
when you need to know what the organism is, ex if the bacteria has a hx of resistance to antibiotics, you may want a narrower, more efficient spectrum antibiotic. a cx can give definite ID of organism within 24 hrs, which helps with initial therapy and antibiotic susceptibility tests can be done within 48 hrs as well. microbiological assessment can be continued for duration of tx, our own normal flora may carry antibiotic resistance genes that can be passed on to the pathogen. local epidemiology on certain species' incidence is also helpful
question
what is an minimal INHIBITORY concentration, (MIC)? how is it done? how is the minimal bacteriCIDAL concentration done?
answer
the organism is grown in broth culture, and serial dilutions of an antibiotic are added to different test tubes. the tube where the least antibiotic and still lack of bacterial growth exist is the minimal inhibitory concentration. minimal bactericidal concentration testing will be done on a plate,
when organism doesn’t grow even in removal of antibiotic, this is the minimal bacteriCIDAL concentration.
question
what is the agar disk diffusion method? how is it done? what does it tell you?
answer
bacteria are plated and little discs of differing antibiotic conc. are placed on it. it is incubated overnight and zones of inhibition are looked for and measured. this will tell you if the organism is sensitive or resistant to the antibiotic, in a QUALITATIVE "antibiogram"
question
what is the gradient elution test? what information does it provide?
answer
tries to make the agar disk diffusion method a little more quantitative, (mix between broth culture and agar disk test).
question
what are pharmacodynamic considerations? for bacteriostatic, bacteriocidal drugs?
answer
consideration of the relationship between antibiotic conc. and antimicrobial effect. (in vitro vs what is reasonable in vivo). bacteriostatic agents arrest the growth or replication of bacteria at serum levels achievable in the pt. bacteriocidal agents kill bacterial at serum levels achievable in the pt, should be used when defenses are impaired.
question
what are the two kinds of bacteriocidal agents?
answer
those that effect conc. dependent killing and those that effect time dependent killing.
question
how does the action of drugs that enact concentration dependent killing look?
answer
the rate and extent increases with increasing concentration, (single dose antibiotics)
question
how does the action of drugs that enact time dependent killing look?
answer
activity continues as long as serum concentrations are at a certain level.
question
what is the post antibiotic effect, (PAE)? what are considerations for drugs that lack this?
answer
some antibiotics bind to a target in the organism and even after the conc of the antibiotic gets to be low, they remain stuck to the target and it still has its effect. drugs without a PAE should remain above the MIC serum concentration for intervals between dosing. this plays a part in the efficacy of some one-daily dose regimes
question
what are pharmacokinetic considerations? how does this affect route of administration?
answer
absorption, distrobution, and elimination of the drug from the body. this includes oral administration and parenteral (IV) administration.
question
why might oral routes of administration be chosen?
answer
less costly and few complications?
question
why might paraenteral, (IV) administration be considered?
answer
if the drug is poorly adsorbed from the intestinal tract, if the pt has disease that would impair absorption, or if the pt is critically ill/suffers from menigitis,(to get through the blood brain barrier) or endocarditis
question
what are some conditions that can alter antimicrobial kinetics? (dosage vs state of vascular availability)
answer
impaired renal/hepatic function leads to reduced elimination, and dosage needs to be decreased. pts with burns, CF, or trauma, dosage should be increased. dosage should also be altered in elderly, neonates, and in pregnancy.
question
when might conc. of bodily fluids need to be taken into account? what organs or areas of the body have special consideration for this?
answer
CSF concentration is limited due to blood/brain barrier. the prostate and eye have limited distrobution as well.
question
what are some considerations in terms of antimicrobial safety? in terms of pt hx?
answer
some anti-microbials are toxic to eukaryotic cells and are thus reserved for life-threatening conditions. an allergy, drug and medical hx should be obtained. groups with frequent adverse rxns include: neonates, elderly, renal failure, and AIDs pts
question
what are some advantages in terms of combining antimicrobial drugs, synergism?
answer
this makes the antibiotic more broad spectrum, can treat polymicrobial infections more effectively, decrease the emergence of antibiotic resistance, (harder to generate resistance against 2 drugs), and reduce dose-related toxicity, (smaller dose of 2 drugs w/different side effects)
question
to obtain rationale for synergistic antibiotic rx, what increase in inhibition or killing should be seen in MIC or MBC vs used alone?
answer
4x
question
what is an example of synergism leading to enhancement of antimicrobial uptake?
answer
aminoglycosides can have a difficult time getting into a cell, but given with penicillin to break up the cell wall, aminoglycosides can enter
question
what are other mechanisms of synergism in terms of metabolic sequences or enzyme inhibition?
answer
blockade of sequential steps in a metabolic sequence or inhibition of enzymatic inactivation, (ex. inhibition of B-lactamase by B lactamase inhibitor drugs)
question
what is an example of antagonism between antibiotics if taken at the same time?
answer
inhibition of cidal activity by static agents, (cidals can require growth to function)
question
can one antibiotic enzymatically inactivate another?
answer
yes
question
what things must an antibiotic do to be effective?
answer
it must associate with the bacteria and penetrate the envelope. it must be transported to an intracellular site of action. it must bind to its target
question
what are mechanisms of antibiotic resistance?
answer
prevention of access to the target, alteration of the target or aquisition of the ability to destroy or modify the antibiotic
question
how can various bacteria prevent access of antibiotics to their targets? how is the action of PCN and ceph affected? aminoglycosides? vancomycin? can mutations in porins prevent entrance of more than one antibiotic into the cell, (cross resistance)?
answer
PCN and cephalosporin can be blocked by mutations in the outer membrane where porins, (OMP f), shrink and the drugs can't get in. outer membrane protein expression can be decreased for aminoglycosides so they can't enter either. porins on gram - bacteria are normally too small for vancomycin even without development of resistance. and cross resistance does happen.
question
what is another way that antibiotic access to the target can be prevented?
answer
active efflux of the antibiotic, bacteria can aquire the "tet" gene which expresses a transporter that flushes tetracycline out of the cell
question
what are examples of antibiotic targets in bacteria being altered for PCN, aminoglycosides, and vancomycin?
answer
with PCN, transpeptidase, (PBP), can be altered. with vancomycin, the termini can be altered. with aminoglycosides, the 30s subunit can be altered
question
how did staphylococcus aureus become methicillin resistant, (MRSA)?
answer
staphylococcus aureus produce PBP2a', which has a low affinity for beta-lactam antibiotics, which allowed cell wall synthesis to continue in their presence. They also produced betalactamases which reduced the efficacy of PCN/cephalosporin. Methicillin was then developed b/c it couldn't be affected by betalactamase. staphylococcus aureus then developed another transpepdidase that did not bind to methicillin. staphylococcus aureus then became methicillin resistant, (MRSA)
question
what is PBP2a'? what encodes it? how is it tested for?
answer
PBP2a' is the altered transpeptidase which as a low affinity for beta-lactam antibiotics. it is encoded by the mecA gene. it is tested for using PCR and antibody test for PBP2a. the organism can express this gene at really low level, so you can look for this gene using PCR instead of looking directly at resistance.
question
what strains of bacteria can develop vancomycin resistance?
answer
strains with VanA,B and D genes can replace the last ala with lac so vancomycin can't bind.
question
what is used as the last resort for MRSA and enterococci?
answer
vancomycin, but VRE have emerged since the late 1980s
question
what are some examples of enzymes that cleave antibiotics in defense of the bacteria? are there ones for specific antibiotics? what is ESBL?
answer
beta lactamases. penicillinase only affects PCN, cephalosporinase only effects cephalosporins. ESBL are extended spectrum beta lactamases these can affect PCN and cephalosporin for ex.
question
how are antibiotics like aminoglycasides be modified by bacterial enzymes?
answer
aminoglycasides be modified via N-acetylation, phosphorylation, and 0-adenylation
question
what are some reasons for phenotypic resistance, (therapeutic resistance despite susceptibility in vitro), in terms of beta-lactams? abcesses? intracellular growth?
answer
bacteria may not be dividing and beta-lactams cannot work b/c they require growth. bacteria could be walled off inside an abcess and then antibiotic can't get to it. the organism could also be growing intracellularly, and again, out of antibiotic range.
question
what is an example of genetically originated resistance in chromosomes? plasmids? transposons?
answer
chromosomal point mutations, low frequency, usually resistance to a single antibiotic. plasmids, frequently mediate resistance to multiple antibiotics (through R factors), most common in gram -. transposons have potential for widespread dissemination of resistance genes, (through R-determinants), can't replicate independent of a plasmid/chromosome, but translocates within a chromosome, plasmid, or phage DNA.
question
what is the epidemiology of resistance?
answer
clinical use of antibiotics is followed by resistance, increase use -> increase resistance. preexisting resistance strains can be selected for by antibiotic usage
Get an explanation on any task
Get unstuck with the help of our AI assistant in seconds
New